PF-06954522 / Pfizer - LARVOL DELTA

Pfizer's embattled obesity program loses another GLP-1 over poor data and strong competition (FierceBiotech) - "Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, citing poor data and tough competition...Now, PF-06954522 has also been discontinued, Pfizer confirmed to Fierce Biotech this morning. When asked whether PF-06954522 encountered similar liver problems to those seen with lotiglipron or danuglipron, a spokesperson told Fierce that the decision to end development 'was not related to any safety concerns that arose in the phase 1 program.'....Instead, Pfizer made the call 'following a review of data from its phase 1 program and the GLP-1 landscape.'"

Discontinued • Obesity

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=50 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | N=122 ➔ 45 | Trial completion date: Dec 2024 ➔ Apr 2025 | Trial primary completion date: Dec 2024 ➔ Apr 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov) - P1 | N=23 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed | N=16 ➔ 23

Enrollment change • Trial completion

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | N=24 ➔ 16

Enrollment change • Enrollment closed

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Pfizer | N=12 ➔ 24

Enrollment change

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Pfizer | Active, not recruiting ➔ Recruiting

Enrollment open

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Active, not recruiting | N=12 ➔ 16

Enrollment change • Enrollment closed

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Pfizer

New P1 trial

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=122 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=122 | Not yet recruiting | Sponsor: Pfizer

New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting

Enrollment closed